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Genetic thrombophilia was no more prevalent than in the
general population.
Finally, we confirm that LAC and aCL >30 GPL units are the
main thrombophilic factors associated with thrombosis in
SLE. The role of free protein S and homocysteinaemia remains
unclear. Prospective studies, with serial sampling, are needed
to elucidate which others factors may play a part.
. . . . . . . . . . . . . . . . . . . . .
Authors’ affiliations
D Barcat, J Constans, C Conri, Médecine Interne et Pathologie
Vasculaire, Hôpital Saint-André, 1, rue Jean Burguet, 33075 Bordeaux,
France
V Guérin, A Ryman, Hématologie, Hôpital Pellegrin, 3, place Amélie
Raba-Léon, 33076 Bordeaux, France
J P Vernhes, Rhumatologie, Hôpital Robert Boulin, 33500 Libourne,
France
C Vergnes, Hématologie, Hôpital du Haut Lévêque, 33600 Pessac,
France
F Bonnet, X Delbrel, P Morlat, M Longy-Boursier, Médecine Interne et
Pathologie Infectieuse, Hôpital Saint-André, 1, rue Jean Burguet, 33075
Bordeaux, France
Correspondence to: Dr D Barcat; damien.barcat@chu-bordeaux.fr
Accepted 20 January 2003
REFERENCES
1 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and
the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE
disorders. Ann Intern Med 1990;112:682–98.
2 Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus
anticoagulant is the strongest risk factor for both venous and arterial
thrombosis in patients with systemic lupus erythematosus. Thromb
Haemost 1996;76:916–24.
3 Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G.
Risk of venous thrombosis related to antiphospholipid antibodies in
systemic lupus erythematosus. Lupus 1997;6:467–73.
4 Tomas JF, Alberca I, Tabernero MD, Cordero M, Del Pino-Montes J,
Vicente V. Natural anticoagulant proteins and antiphospholipid
antibodies in systemic lupus erythematosus. J Rheumatol
1998;25:57–62.
5 Sorice M, Griggi T, Circella, Lenti L, Arcieri P, Domenico di Nucci G, et
al. Protein S antibodies in acquired protein S deficiencies. Blood
1994;83:2383–4.
6 Kiraz S, Ertenli I, Benekli M, Haznedaroglu IC, Calguneri M, Celik I, et
al. Clinical significance of hemostatic markers and thrombomodulin in
systemic lupus erythematosus: evidence for a prothrombotic state. Lupus
1999;8:737–41.
7 Ferro D, Quintarelli C, Valesini G, Violi F. Lupus anticoagulant and
increased thrombin generation in patients with systemic lupus
erythematosus. Blood 1994;83:304–5.
8 Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH.
Plasma homocysteine as a risk factor for atherothrombotic events in lupus
erythematosus. Lancet 1996;348:1120–4.
9 Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH. Homocysteine,
methylenetetrahydrofolate reductase polymorphism, antiphospholipid
antibodies, and thromboembolic events in systemic lupus erythematosus:
a retrospective cohort study. J Rheumatol 1998;25:1737–42.
HLA class II allele polymorphism in Hungarian patients
with systemic lupus erythematosus
E Endreffy, A Kovács, L Kovács, G Pokorny
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2003;62:1017–1018
Recently, a comprehensive study was published on HLAclass II DNA typing in a large cohort of European patientswith SLE.1 Independently of this collaborative study, we
have examined similar DRB1, DQA1, and DQB1 allele
polymorphisms and clinical features in Hungarian patients
with SLE.
Fifty patients with SLE (48 female; mean age at the time of
the examinations 41 years (range 21–76)) and 50 healthy
blood donors matched for age and sex with the controls were
examined. Genotyping of HLA-DRB1 alleles was carried out
with the Dynal RELI SSO HLA-DRB kit, and the DRB1*15/16
subtyping by the method of Ota et al.2 DQA1 determination
was performed by the method of Ota et al.3 The DQB1 typing
was carried out with the INNO-LiPA DQB kit. A χ2 test with
Yates’s correction was used for statistical analysis. The signifi-
cance levels (p<0.05) were adjusted by using Bonferroni’s
correction to eliminate chance associations (pc value). Odds
ratio (OR) values were also calculated.
The main clinical manifestations were articular involve-
ment (92%), anaemia (72%), leucopenia (54%), pericarditis
and/or pleuritis (54%), and nephritis (32%).
The DRB1*1501, DRB1*03, and DRB1*07 alleles occurred
more frequently in the patients with SLE than in the controls
(12/50 (24%) v 3/50 (6%); 20/50 (40%) v 10/50 (20%) and 17/50
(34%) v 6/50 (2%), respectively; ORs 4.4, 2.25, and 3.2, respec-
tively). The DQA1*0102 and *05011 alleles were also more
common in the SLE group than in the controls (25/50 (50%) v
13/50 (26%), and 20/50 (40%) v 9/50 (18%), respectively; ORs
2.23 and 2.3, respectively). Of the DQB1 alleles, *0201 and
*0602 were detected more frequently in the patients with SLE
than in the controls (20/50 (40%) v 8/50 (16%), and 11/50
(22%) v 2/50 (4%), respectively; ORs 2.87 and 6.05, respec-
tively). After the Bonferroni’s correction the above mentioned
differences did not reach significance.
In contrast, the DRB1*04 and DRB1*11/12 alleles were less
common in the patients with SLE than in the controls (3/50
(6%) v 16/50 (32%) and 15/50 (30%) v 25/50 (50%)). The *04
allele was linked with resistance to leucopenia (pc=0.01), the
*11/12 alleles with resistance to discoid skin lupus
(pc=0.001). The 1106 subtype of the DRB1*11 alleles occurred
only in the patients with SLE (4/16 (25%) v 0/25 (0%)).
Connections between the genetic and clinical characteris-
tics were as follows: the DRB1*1501 positivity was less
frequent in the patients with than in those without lupus
nephritis (LN) (3/16 (19%) v 15/34 (44%)). In contrast, the
DRB1*03 and DRB1*07 alleles were more frequent in the
patients with than in those without LN (8/16 (50%) v 11/34
(32%) and 7/16 (44%) v 8/34 (24%)). In the patients with
pleuritis and/or pericarditis, only the DRB1*07 positivity was
more frequent than in the patients without serositis (12/27
(44%) v 3/23 (13%)). The *07 allele was detected more
frequently in the patients with one or more severe renal,
cardiorespiratory manifestations than in the patients without
these potentially fatal features of the disease (16/36 (44%) v
0/14 (0%)). In the patients with anti-SSA and anti-SSB posi-
tivity the renal and cerebral involvement was more common,
but the differences were not significant (4/8 (50%) v 9/33
(27%) and 2/8 (25%) v 3/33 (9%)).
A comparison with the results of the comprehensive Euro-
pean study showed that agreement was complete for the
increased prevalence of the DRB1*1501, DRB1*03,
DQA1*0102, DQB1*0201, and DQB1*0602 alleles in the
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patients with SLE. We could not detect increased frequencies
of the DQB1*0303 and DQB1*0502 alleles in our patients with
SLE, and our patients with DRB1*1501 positivity exhibited a
milder clinical course and a negative correlation with LN.
. . . . . . . . . . . . . . . . . . . . .
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Conduction disturbances are a well recognised extra-articular manifestation of ankylosing spondylitis andother spondyloarthropathies (SpA),1 2 disorders which
are strongly associated with the HLA-B27 gene. Some, though
not all studies, suggest an association between the presence of
SpA and/or HLA-B27 and the occurrence of cardiac conduc-
tion disorders.3–7 This study aimed at determining the
prevalence of SpA in a group of patients with a permanent
pacemaker, and discovering whether these patients were more
likely to be HLA-B27 positive than a group of controls.
Seventy six men and 51 women (mean age 73 years) with a
permanent pacemaker who attended the cardiology depart-
ment at the Hospital of Angra do Heroísmo (Terceira island,
Azores) were assessed clinically for the presence of spondylo-
arthritis. All had pelvic radiographs performed and blood
taken for HLA-B27 typing (polymerase chain reaction with
sequence-specific primers).8 Pelvic radiographs were assessed
by two qualified observers (JBA and CL) and, if sacroiliitis was
suspected a computed tomographic scan of the sacroiliac joint
was performed. SpA was diagnosed according to the European
Spondylarthropathy Study Group (ESSG) criteria.9 Fifty men
and 80 women (mean age 53 years) recruited from a popula-
tion based register for participation in a screening survey of
vertebral osteoporosis acted as a control group. These subjects
had blood taken for HLA-B27.
Eighty one of the patients had evidence of atrioventricular
conduction disturbances and the remaining patients had a
pacemaker implanted for other reasons (auricular fibrillation/
flutter, sick sinus disease, congenital diseases). Two patients
with pacemaker had bilateral sacroiliitis; one a 56 year old
man had had surgery for aortic insufficiency four years previ-
ously and had complete atrioventricular block. He was
HLA-B7 positive, but had no history of inflammatory back
pain or spondylitis on x ray examination. The other, a 72 year
old man was HLA-B27 positive, though did have inflammatory
back pain and severe spondylitis. The underlying cardiac
abnormality was mobitz type 2 atrioventricular block. Based
on the ESSG criteria the prevalence of SpA was 0.8%. HLA-B27
was present in six (5%) patients with a permanent pacemaker
and nine (7%) of the control group (χ2=0.24; p=0.63).
In summary, in this observational study patients with a
permanent pacemaker were no more likely to be HLA-B27
positive than a group of population controls.
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